{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Based upon the strategic reevaluation of the clinical development program for surufatinib in Europe and the United States (US), the study was terminated. The termination was not based on any concern for patient safety or efficacy relative to surufatinib treatment."},"pointOfContact":{"email":"nickl@hutch-med.com","organization":"HUTCHMED International Corporation","phone":"+44 7826 422448","title":"Nick Lawn"}}